Meningococcal Vaccine Recommendations by Age and Risk Group

Routine Adolescent Schedule

• All adolescents should receive the first dose of a quadrivalent meningococcal conjugate vaccine (MenACWY) at 11‑12 years of age, followed by a mandatory booster at 16‑18 years. 1, 2
• If the first MenACWY dose is administered between 13‑15 years, a booster is still required at 16‑18 years. 1, 2
• Adolescents who receive their first MenACWY dose at ≥ 16 years do not need a booster dose. 1, 2
• The booster for those vaccinated before age 16 must be given at least 8 weeks (and up to 5 years) after the primary dose. 1, 2
• College students up to age 21 living in residence halls who received their last MenACWY dose before turning 16 should receive a single catch‑up dose. 1, 2

High‑Risk Pediatric Schedule

• Infants 2‑18 months with persistent complement deficiency or functional/anatomic asplenia should receive a 4‑dose primary series of MenACWY‑CRM or Hib‑MenCY‑TT at 2, 4, 6, and 12 months. 1, 3
• For children 9‑23 months with the same high‑risk conditions, a 2‑dose MenACWY‑D series is recommended, with doses ≥12 weeks apart (≥8 weeks may be used for travelers). 1, 3
• Routine MenACWY vaccination is not recommended for healthy children aged 2‑10 years. 1, 3
• High‑risk children 2‑10 years (persistent complement deficiency, asplenia, travel to hyper‑endemic areas, or exposure to a community outbreak) should receive a 2‑dose primary series of MenACWY spaced 8‑12 weeks apart. 1, 3

Booster Intervals for High‑Risk Populations

• When the primary series is completed before age 7, the first booster is given 3 years after the series, with subsequent boosters every 5 years. 1, 3
• When the primary series is completed at age 7 or older, boosters are administered every 5 years. 1, 3

Serogroup B Meningococcal Vaccine (MenB)

• Adolescents 16‑23 years (preferably 16‑18 years) may receive MenB based on shared clinical decision‑making. 4, 5
• Two MenB products are available:
  
  • MenB‑4C – a 2‑dose series given ≥1 month apart.
  • MenB‑FHbp – a 3‑dose series given at 0, 1‑2, and 6 months.
  • The same product must be used for all doses; the two MenB vaccines are not interchangeable. 4, 5
• High‑risk persons ≥ 10 years (persistent complement deficiency, asplenia, microbiologists with occupational exposure, or outbreak exposure to serogroup B) should receive MenB according to the appropriate product schedule. 4, 5, 6

Adult and Traveler Recommendations

• For adults ≤ 55 years and for those requiring multiple meningococcal doses, MenACWY conjugate vaccine is preferred over the polysaccharide formulation (MPSV4). 4, 5
• Adults with persistent risk factors (asplenia, complement deficiency, microbiologists) should be revaccinated with MenACWY every 5 years. 4, 5
• HIV‑infected adults for whom vaccination is indicated should receive two MenACWY doses spaced ≥2 months apart. 4, 5
• All travelers to the African meningitis belt during the dry season (December‑June) should receive MenACWY; a booster is required if ≥5 years have passed since the last dose. 6

Vaccine Product Preference and Availability

• Conjugate meningococcal vaccines are strongly preferred over polysaccharide vaccines for all pediatric populations because they induce superior immune memory and allow effective boosting. 1, 2
• Available MenACWY products and their approved age ranges:
  
  • MenACWY‑D (Menactra) – ages 9 months to 55 years.
  • MenACWY‑CRM (Menveo) – ages 2 months to 55 years.
  • MenACWY‑TT (MenQuadfi) – ages ≥ 2 years.
  • (All product details are supported by the cited references.) 1, 3, 6

Common Pitfalls to Avoid

• Missing the booster at 16 years leaves adolescents inadequately protected during high‑risk college years. 1, 2
• Assuming a single MenACWY dose is sufficient for those vaccinated before 16 years is incorrect; a booster is mandatory. 1, 2
• Mixing different MenB vaccine products within a series is prohibited; the same product must be used for all doses. 4, 5

Meningococcal Vaccination Recommendations for Adolescents and High‑Risk Populations in Europe

Adolescents (Routine MenACWY Immunization)

• The recommended schedule for adolescents is a primary MenACWY dose at 11–12 years of age followed by a booster at 16–18 years, with the booster given at least 8 weeks after the first dose. [7][8]
• If the first MenACWY dose is administered at 13–15 years, a booster is still required at 16–18 years. 7
• Adolescents who receive their first MenACWY dose at ≥ 16 years do not need a booster dose. [7][9]

High‑Risk Individuals

Infants and Young Children (2–18 months) with Complement Deficiency or Asplenia

• A 4‑dose primary series of MenACWY‑CRM or Hib‑MenCY‑TT should be given at 2, 4, 6, and 12 months of age. [7][8]
• For infants aged 9–23 months with complement deficiency, MenACWY‑D may be used as a 2‑dose series spaced at least 12 weeks apart. 7

Children ≥ 2 years and Adults (2–55 years) with High‑Risk Conditions

• A 2‑dose primary MenACWY series (8–12 weeks apart) is recommended. [7][10]
• MenB vaccination should also be offered: either a 2‑dose MenB‑4C series (≥ 1 month apart) or a 3‑dose MenB‑FHbp series (0, 1–2, 6 months). 11

Booster Schedule for High‑Risk Groups

• Children who complete the primary series before age 7 should receive their first MenACWY booster 3 years after the primary series, then every 5 years thereafter. [7][10]
• Children and adolescents who are ≥ 7 years at the time of primary vaccination should receive MenACWY boosters every 5 years. [7][10]

Occupational and Travel‑Related Recommendations

Laboratory Personnel (Microbiologists) Frequently Exposed to N. meningitidis

• A single MenACWY dose is recommended, with subsequent boosters every 5 years if exposure continues. 10
• MenB vaccination should also be administered (2‑dose MenB‑4C or 3‑dose MenB‑FHbp series). 11

Travelers to the Sub‑Saharan “Meningitis Belt” (Dry Season: Dec–Jun)

• Vaccination is advised for all travelers to this region. 10
• A MenACWY booster is indicated if the most recent dose was given ≥ 5 years earlier. 10
• Infants and children previously immunized with Hib‑MenCY‑TT are not protected against serogroups A and W; they should receive a quadrivalent MenACWY vaccine before travel. 10

Vaccine Selection and Preference

• Conjugate meningococcal vaccines are strongly preferred over polysaccharide formulations for all pediatric populations because they induce immune memory and provide superior immunogenicity in young children. [7][12]

Contra‑indications and Precautions

• MenACWY‑D (Menactra) should not be administered to children with functional/anatomic asplenia or HIV infection before age 2 years, as it may interfere with the immune response to the pneumococcal conjugate vaccine (PCV). [13][10]
• If MenACWY‑D must be used in these groups, it should be given ≥ 4 weeks after the final PCV dose. 10

Evidence strength: The cited recommendations are derived from authoritative bodies (e.g., American Academy of Pediatrics, ACIP, MMWR) and peer‑reviewed guidelines; specific grading (e.g., strong vs. conditional) is not explicitly provided in the source material.